BioLight Life Sciences

BELKIN Laser Ltd. is an innovative company based in Yavne, Israel, founded in 2013, that focuses on developing a groundbreaking one-second laser device for the treatment of glaucoma. This automated device aims to provide ophthalmologists with a means to deliver drop-less and contactless care, addressing the significant disparity between the large number of glaucoma patients, estimated at 67 million, and the relatively limited number of ophthalmologists available. The technology is particularly relevant for Open Angle Glaucoma, which affects 70% of glaucoma patients, and has the potential to pioneer treatment for Angle Closure Glaucoma, notably prevalent among Asian populations. BELKIN's solution is designed to be non-invasive, instantaneous, and painless, offering a patient-friendly alternative to traditional methods. By simplifying the treatment process, BELKIN Laser seeks to transform glaucoma care from a specialized procedure to a widely accessible option that can be performed by all ophthalmologists and healthcare providers, thereby enhancing patient access to essential care.

IOPtima Ltd. specializes in the development of minimally-invasive surgical ophthalmic devices, focusing primarily on glaucoma treatment. Its flagship product, the IOPtimate, employs CO2 laser technology to reduce intraocular pressure by restoring the natural flow of eye fluids without penetrating the eye. This system is designed to enhance the safety and efficacy of glaucoma surgeries, utilizing a procedure called CLASS (CO2 Laser-Assisted Sclerotomy Surgery) that targets the sclera wall in a controlled manner. Additionally, IOPtima offers the iLid CO2 laser kit, which aids oculoplastic surgeons in performing cosmetic eyelid procedures. Founded in 2002 and based in Tel Aviv, Israel, IOPtima operates as a subsidiary of Bio Light Israeli Life Sciences Investments Ltd. The company's innovative approaches aim to address unmet needs in glaucoma care while minimizing side effects and recovery times for patients.